Navigation Links
Chesley Files Federal Zicam Lawsuits
Date:3/4/2010

CINCINNATI, March 4 /PRNewswire/ -- Stanley M. Chesley from the Cincinnati, Ohio-based law firm of Waite, Schneider, Bayless & Chesley Co., L.P.A. yesterday filed federal lawsuits in Ohio and Kentucky against Matrixx Initiatives, the manufacturer of Zicam, on behalf of four local residents who lost their senses of taste and smell after using the popular over-the-counter cold and flu nasal gel.

The lawsuits allege that Matrixx knew for years that Zicam users had complained of anosmia, or loss of smell, but explicitly chose not to warn Zicam customers.  

On June 16, 2009 the Food and Drug Administration issued a warning advising consumers to "stop using and discard" Zicam Cold Remedy Nasal Gel and Cold Remedy Nasal Swabs (among others) because Zicam is "associated with the loss of sense of smell."   In light of the FDA's warning, the lawsuit alleges, Matrixx had no choice but to immediately recall the dangerously defective Zicam products.

"The problem here is that Matrixx repeatedly refused to protect consumers of its products until the FDA forced its hand," noted Chesley.  "With these lawsuits, our clients intend to send a message that the American public will not stand by while another drug manufacturer secretly attempts to put its profits ahead of public safety."

The cases, Raker et al v. Matrixx Initiatives, Inc. et al., (Case Number 10-cv-000125, S.D. Ohio) and Hartman v. Matrixx Initiatives, Inc. et al., (Case Number 10-cv-00042, E.D. Ky.), allege negligence, defect in design and manufacture, failure to warn, breach of warranties, fraudulent concealment, and state consumer laws

CONTACT: Stanley M. Chesley, Robert A. Steinberg, or Renee A. Infante at (513) 621-0267

SOURCE Waite, Schneider, Bayless & Chesley Co., L.P.A.

Back to top
'/>"/>
SOURCE Waite, Schneider, Bayless & Chesley Co., L.P.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
4. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
7. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
8. FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)
9. Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer
10. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
11. deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimers and Other Cognitive Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... 2017  The global market for liquid biopsy diagnostic ... million in 2016.  Although in early stages, the global ... particular as a result of the gradual shift towards ... introduction of a significant number of new liquid biopsy ... tumor biomarkers to guide treatment decisions. ...
(Date:7/10/2017)... , July 10, 2017 The Institute for ... methods, is the recipient of a VITROCELL® inhalation exposure ... International Science Consortium. The device, which is designed to ... expose human lung cells to airborne test materials in ... use the VITROCELL® system for testing combustible tobacco products, ...
(Date:7/5/2017)... , July 5, 2017 Wolfmet 3D  printed ... as physics and manufacturing combine to progress molecular radiotherapy imaging. ... SPECT systems are unable to accurately quantify the radiation absorbed ... information regarding the success of this radiotherapy treatment has been ... ...
Breaking Medicine Technology:
(Date:7/24/2017)... Cambridge, MA (PRWEB) , ... July 24, 2017 , ... ... for an invigorating and educational conference, InstructureCon. Each annual event is coupled with a ... next level with a James Bond theme, Mission: InstructureCon 0017. , To extend ...
(Date:7/24/2017)... ... July 24, 2017 , ... Puregraft, the ... announces the issuance of United States Patent Number 9,695,398 (the '398 patent) and ... The '398 and '324 patents cover methods and systems for optimizing fat ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Paul Vitenas, ... the nation’s top level plastic surgeons, invited to attend Allergan’s recent meeting with their ... most valued companies in the world, Allergan is bringing a newly defined structure to ...
(Date:7/24/2017)... VA (PRWEB) , ... July 24, 2017 , ... ... Managers, **Presented by FDAnews and MSceppa Consulting **, Aug. 22-23, 2017 – Arlington, ... on Friday, July 28. , Increased FDA scrutiny and growing demands to track ...
(Date:7/24/2017)... ... ... “Nana Nana Boo Boo”: a delightful tale of a young girl who ... Boo” is the creation of published author Michael Rush, a Deputy Sheriff, former world ... Rush’s new book presents the importance of manners in a way easily understood by ...
Breaking Medicine News(10 mins):